-- The United Laboratories International (HKG:3933) said Thursday a subsidiary's clinical trial application for its long-acting weekly insulin product secured approval in China.
Specifically, China's National Medical Products Administration cleared the testing for United Bio-Technology (Hengqing)'s UBT38006 injection.